{"DataElement":{"publicId":"5121991","version":"1","preferredName":"Patient Cardiovascular Disorder Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator of whether or not the patient has uncontrolled or significant cardiovascular disease.","longName":"CARDIO_DZ_IND","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"4851520","version":"1","preferredName":"Patient Cardiovascular Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4851518v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4851518","version":"1","preferredName":"Cardiovascular Disorder Clinical Trial Eligibility Criteria","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C2931:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cardiovascular Disorder","conceptCode":"C2931","definition":"A non-neoplastic or neoplastic disorder affecting the heart or the vessels (arteries, veins and lymph vessels). Representative examples of non-neoplastic cardiovascular disorders are endocarditis and hypertension. Representative examples of neoplastic cardiovascular disorders are endocardial myxoma and angiosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-ECF8-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"ONEDATA","dateModified":"2015-06-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17A92515-ED09-611C-E050-BB89AD4314F7","latestVersionIndicator":"Yes","beginDate":"2015-06-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-06-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9853_Theradex_06.03.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]},{"publicId":"6147165","version":"1","longName":"Wake Forest Baptist Medical Center","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6147167","version":"1","longName":"WFB","context":"NCIP"}]}],"AlternateNames":[{"name":"CARDIO_DZ_IND","type":"USED_BY","context":"CCTG"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"NCIP","type":"USED_BY","context":"NCIP"},{"name":"IE_IEORRES_CARDIODX","type":"OID, CCTG","context":"CCTG"},{"name":"IE_IEORRES_CARDIO","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Does the patient have uncontr","type":"Preferred Question Text","description":"Does the patient have uncontrolled or significant cardiovascular disease or cardiovascular disease-related requirement for daily supplemental oxygen?","url":null,"context":"ABTC"},{"name":"Alt Question 1501","type":"Alternate Question Text","description":"Does the patient have uncontrolled or significant cardiovascular disease including, but not limited to: myocardial infarction or stroke/transient ischemic attack (TIA) within the 6 months prior to consent, uncontrolled angina with the 3 months prior to consent, any history or clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), QTc prolongation > 480 msec, history of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant coronary stent occlusion, deep venous thrombosis, etc.), or cardiovascular disease-related requirement for daily supplemental oxygen.","url":null,"context":"ABTC"},{"name":"ABTC 1501 Question","type":"Alternate Question Text","description":"Does the patient have uncontrolled or significant cardiovascular disease including, but not limited to: myocardial infarction or stroke/transient ischemic attack (TIA) within the 6 months prior to consent, uncontrolled angina with the 3 months prior to consent, any history or clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), QTc prolongation > 480 msec, history of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, deep venous thrombosis, etc.), or cardiovascular disease-related requirement for daily supplemental oxygen.","url":null,"context":"ABTC"},{"name":"CCTG-1","type":"Alternate Question Text","description":"Does the patient have clinically significant untreated or uncontrolled cardiovascular conditions, and/or symptomatic cardiac dysfunction?","url":null,"context":"CCTG"},{"name":"CITN Patient has New York Heart Association (NYHA) class 3 or 4 or clinically symptomatic cardiovascular disease","type":"Alternate Question Text","description":"Patient has New York Heart Association (NYHA) class 3 or 4 or clinically symptomatic cardiovascular disease","url":null,"context":"CITN"},{"name":"WF-97415","type":"Alternate Question Text","description":"Overt coronary artery disease or heart failure","url":null,"context":"NCIP"},{"name":"ABTC 1804 Text 1","type":"Alternate Question Text","description":"Does the patient have any history, current symptoms, or signs of ventricular tachyarrhythmias?","url":null,"context":"ABTC"},{"name":"CCTG_02","type":"Alternate Question Text","description":"Patient with known history of current symptoms of cardiac disease, or history of treatment with cardiotoxic agents must be class 2B or better per the New York Heart Association Functional Classification.","url":null,"context":"CCTG"},{"name":"CCTG_03","type":"Alternate Question Text","description":"Patient has uncontrolled congestive heart failure no worse than NYHA IIB.","url":null,"context":"CCTG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have clinically significant cardiac dysfuction?","url":null,"context":"COG"},{"name":"CCTG_04","type":"Alternate Question Text","description":"Clinically significant (i.e. active) cardiovascular disease for example cerebro vascular accidents (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, New York Heart Association (NYHA) grade II or higher, congestive heart failure, serious cardiac arrhythmia requiring medication.","url":null,"context":"CCTG"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B842A82-5D5E-194A-E050-BB89AD435DD3","latestVersionIndicator":"Yes","beginDate":"2016-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-11","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":"Created for 1501 study in Rave per request by R.Marasigan. mc 2/11/16","administrativeNotes":"9/26/23 Added alt oid,CCTG and AQT for ticket number CADSR0002884 cjl. 2023.8.14 AQT added per ticket request CADSR0002739. ak 12/20/22 added AQT for ticket number CADSR0001818 cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}